New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
05:27 EDTLGNDLigand announces data from preclinical LGD-7455 studies
Ligand Pharmaceuticals announced that data from preclinical studies on its granulocyte colony stimulating factor receptor agonist program were featured in a poster presentation at the Annual Meeting of the American Society of Hematology. In preclinical studies, Ligand evaluated the ability of LGD-7455 to stimulate neutrophil counts in cynomolgus monkeys and investigated the role that metal ions play in the activity of LGD-7455 on the G-CSF receptor. Additionally, the effects and mechanisms of LGD-7455 on tumor cell growth were examined. The key findings include: LGD-7455 is a novel small-molecule, selective human G-CSFR agonist that activates the receptor in a manner distinct from native G-CSF, but similar to the mechanism of small-molecule oral thrombopoietin receptor agonists; LGD-7455 significantly increases peripheral blood neutrophils, demonstrating the first reported proof-of-concept for a small molecule G-CSFR agonist in a primate model; LGD-7455 inhibits tumor cell growth and increases apoptosis, mediated by intracellular metal chelation and an increase in reactive oxygen species formation.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
03:59 EDTLGNDLigand volatility at historic high
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use